What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To compare the clinical outcomes of fludarabine-melphalan versus fludarabine-busulfan regimens in hematologic malignancies following transplantation.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review found melphalan improves progression free survival in hematologic malignancies, suggesting tailored regimens may be needed.

To compare the clinical outcomes of fludarabine-melphalan versus fludarabine-busulfan regimens in hematologic malignancies following transplantation.
Conducted a systematic review and meta-analysis of studies comparing outcomes of allo-HSCT using FluMel versus FluBu.
Included studies on adult patients with hematologic malignancies and analyzed transplant outcomes such as OS and PFS.
Utilized random-effects model in R for meta-analysis, evaluated heterogeneity and publication bias using standard statistical tests.
FluMel showed significant improvement in progression free survival compared to FluBu with HR 0.89; no significant difference in overall survival.
In subgroup analyses, FluMel improved overall survival and progression free survival in AML/MDS patients while showing higher treatment-related mortality.
FluMel was less effective in lymphoma patients, associated with lower overall survival due to higher treatment-related mortality.

Wannaphut et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review found melphalan improves progression free survival in hematologic malignancies, suggesting tailored regimens may be needed.